| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Vistagen Therapeutics Inc. | PH94B | Adjustment Disorder with Anxiety (AjDA) | Phase 2a | Data Released | Intranasal | Psychiatric |
| Vistagen Therapeutics Inc. | Itruvone (PH10) | Major depressive disorder (MDD) | Phase 2a | Ongoing | Intranasal | Psychiatric |
| Vor Biopharma Inc. | Telitacicept | Generalized Myasthenia Gravis | Phase 3 | Ongoing | Subcutaneous | Neurology |
| Vor Biopharma Inc. | Telitacicept | IgA Nephropathy | Phase 3 | Data Released | Subcutaneous | Immunology |
| Vor Biopharma Inc. | Telitacicept | Primary Sjögren's disease | Phase 3 | Data Released | Subcutaneous | Immunology |
| Voyager Therapeutics Inc. | VY-AADC02 - (RESTORE-1) | Parkinson's Disease | Phase 2 | Trial Discontinued | Intracerebral | Neurology |
| vTv Therapeutics Inc. | Cadisegliatin (TTP399) | Type 1 Diabetes | Phase 3 | Ongoing | Oral | Endocrinology |
| vTv Therapeutics Inc. | Cadisegliatin (TTP399) | Type 1 Diabetes | Phase 3 | Ongoing | Oral | Endocrinology |